Board of Directors
Axel Bolte, MSc., M.B.A.
President and CEO, Inozyme Pharma, Inc. and Investment Advisor, HBM Healthcare Investments AG
Thomas Dyrberg, M.D., DMSc.
Senior Partner, Novo Ventures and Novo A/S
Adrienne L. Graves, Ph.D.
Former Chief Executive Officer of Santen, Inc.
As the former Chief Executive Officer of Santen Inc., the US subsidiary of the 130-year-old Japanese pharmaceutical company, she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Senior Vice President of Worldwide Clinical Development (US, Europe and Japan) for seven years and Chief Executive Officer for eight years. Prior to Santen, she spent nine years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology.
Dr. Graves currently serves as an Independent Director on multiple corporate boards including: Akorn, Inc., Greenbrook TMS, Nicox S.A., Oxurion NV, and Surface Pharmaceuticals. She is also a Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, Foundation Fighting Blindness Retinal Degeneration Fund, Retinal Global and KeepYourSight Foundation.
Dr. Graves cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic World Leaders (OWL). She received her A.B. in Psychology from Brown University, her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.
David R. Guyer, M.D.
Executive Chairman of Ophthotech's Board of Directors
Jane Pritchett Henderson
Chief Financial Officer at Turnstone Biologics
Former Partner, Wilmer Cutler Pickering Hale and Dorr LLP
Calvin Roberts, M.D.
Senior Vice President, Chief Medical Officer, Eye Care at Bausch Health Companies
Dr. Roberts is a Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts is a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a founding member of the board of directors of Alimera Sciences. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals.
Dr. Roberts received an A.B. from Princeton University and his M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.
Mike Ross, Ph.D.
Managing Partner, SV Life Sciences
Glenn P. Sblendorio, M.B.A.
President and Chief Executive Officer of Ophthotech